Partially Loaded Antibody-Drug Conjugates via Disulfide Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing antibody-drug conjugates (ADCs) result in fully loaded conjugates without specificity for certain sites of conjugation, leading to potential toxicity and reduced therapeutic efficacy, as they do not consider partially loaded configurations that could offer equal or better therapeutic outcomes with lower toxicity.
Innovation Solution
The development of partially loaded antibody-drug conjugates with selectively assigned points of conjugation, achieved through partial reduction and reoxidation of antibody disulfide bonds, allowing for the conjugation of cytotoxic or cytostatic agents to specific interchain thiols, resulting in a range of drug-loaded species with improved homogeneity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If all interchain disulfide bonds of an antibody are reduced and all reduced thiols are reacted with a drug compound, then the cytotoxic potential of the antibody is maximized, but the toxicity increases and therapeutic window narrows
Solution Approach 1:
The patent applies local quality by creating heterogeneity in drug loading across different antibody molecules. Instead of uniform full loading, some antibody molecules carry fewer drug molecules (partially loaded species), which reduces off-target toxicity while maintaining sufficient cytotoxic potential against tumor cells. This is achieved by controlling the drug-to-antibody ratio during conjugation to produce a mixture of species with different drug loads (e.g., 0-8 drugs per antibody).
Solution Approach 2:
The patent changes the parameter of drug loading from a fixed maximum value to a distributed range of values. By adjusting conjugation conditions (reducing agent amount, reaction time, drug-to-antibody ratio), the distribution of drug-loaded species can be controlled to optimize the balance between cytotoxic efficacy and toxicity reduction.
2Ease of manufacture
If all interchain disulfide bonds are reduced and uniformly substituted with drugs, then the manufacturing process is simplified, but the therapeutic efficacy is reduced due to lack of specificity
Solution Approach 1:
The patent applies partial action by not reducing all interchain disulfide bonds before drug conjugation. Instead of complete reduction followed by uniform drug attachment, the process uses controlled partial reduction or direct conjugation to some thiols, resulting in antibody molecules with varying numbers of drug attachments. This maintains manufacturing simplicity while improving therapeutic efficacy through the creation of partially loaded species.
3Power
If the antibody is fully loaded with 8 drugs per molecule, then the drug potency is maximized, but the homogeneity of the conjugate population is reduced due to multiple possible isomers
Solution Approach 1:
The patent segments the drug-loaded antibody population into multiple discrete species based on drug load (e.g., 0, 2, 4, 6, 8 drugs per antibody). This segmentation creates a heterogeneous mixture of well-defined species rather than a single complex isomeric mixture. Each species has a specific drug count, improving compositional stability and predictability while maintaining overall therapeutic potency through the combined effect of all species.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the therapeutic window of ADCs by reducing toxicity while maintaining efficacy, allowing for the generation of multiple drug-loaded species with improved homogeneity and specificity, thereby improving the treatment of cancer and immune disorders.
Implementation Method 1
partially reducing the protein with a reducing agent
Implementation Method 2
conjugating the drug reactive with free thiols to the partially reduced protein
Data Source
AI summary
A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.